Nagul Meeravali Shaik

Nagul Meeravali Shaik

Auto-generated profile, based on publicly available information

Nagul Meeravali Shaik

Department of Pharmacognosy, V. V. Institute of Pharmaceutical Sciences, Seshadri Rao Knowledge Village, Gudlavalleru, Andhra Pradesh, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2025 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
RPRaveesha Peeriga
Raveesha Peeriga
Krishnaveni ManuboluKrishnaveni Manubolu
Krishnaveni Manubolu
VNVenkateshan Narayanan
Venkateshan Narayanan
PKPRASHANTH KUMAR KATTA
PRASHANTH KUMAR KATTA
NJNuraddeen Ibrahim Jaafar
Nuraddeen Ibrahim Jaafar
NSNagul Meeravali Shaik
Nagul Meeravali Shaik
The physiological and immunological profile of children makes pediatric viral infections particularly difficult. Although pediatric populations are a high risk for hospitalization, pediatric-specific antiviral therapy is largely unexplored, resulting in long delays between pediatric drug approvals and commercialization. This chapter discusses inadequacies in the antiviral drug development and administration for pediatric patients and highlights the importance of age specific approaches including regulatory hindrances to approving children's drugs, and the inhumane nature of performing trials in children. The role that Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA) played in promoting pediatric focused drug research are highlighted. The chapter seeks to encourage cooperation between pediatricians, pharmaceutical developers, and regulatory bodies, in support of the notion that therapeutic antiviral should be truly pediatric centric. Optimizing treatment outcomes is essential to the global health of young patients and these efforts are required.

10 July 2025
Verified
Book Chapter
Closed access
PDF file
RPRaveesha Peeriga
Raveesha Peeriga
Krishnaveni ManuboluKrishnaveni Manubolu
Krishnaveni Manubolu
SSShaik Sabreen
Shaik Sabreen
SBSajja Jayanth Babu
Sajja Jayanth Babu
NSNagul Meeravali Shaik
Nagul Meeravali Shaik
SASaidatri Arige
Saidatri Arige
The process of modern drug discovery heavily depends on chemical biology as a technique to connect chemical science with biological research through its provision of investigative instruments for targeting and verifying drug candidate molecules. The forms of chemical probes combined with tool compounds enable new approaches in drug research because they enable precise molecular-level studies of biological processes, thus promoting better drug development. The fundamental components of drug discovery advancement rely on both chemical probes used to specify protein modifications and experimental tool compounds that help understand biological systems. Extensive disease mechanisms such as those in oncology, neurodegenerative diseases, and infectious diseases become transparent through these investigation methods, which traditional approaches fail to reveal. Extensive expansion of chemical probe libraries targeting multiple disease types will enable better comprehension of complex biological structures. The advances demonstrate significant potential for precision medicine by delivering better and segmental therapeutic approaches to treat complex diseases. The field of drug discovery experiences transformative improvements through chemical biology methods that introduce novel strategies for medical management difficulties. <!----> <!----> <!----> <!---->